Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central anxious technique, conolidine modulates alternate molecular targets. A Science Developments review found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, w